TY - JOUR
T1 - Assessment of VAV2 expression refines prognostic prediction in adrenocortical carcinoma
AU - Sbiera, Silviu
AU - Sbiera, Iuliu
AU - Ruggiero, Carmen
AU - Doghman-Bouguerra, Mabrouka
AU - Korpershoek, Esther
AU - De Krijger, Ronald R.
AU - Ettaieb, Hester
AU - Haak, Harm
AU - Volante, Marco
AU - Papotti, Mauro
AU - Reimondo, Giuseppe
AU - Terzolo, Massimo
AU - Luconi, Michaela
AU - Nesi, Gabriella
AU - Mannelli, Massimo
AU - Libé, Rossella
AU - Ragazzon, Bruno
AU - Assié, Guillaume
AU - Bertherat, Jerome
AU - Altieri, Barbara
AU - Fadda, Guido
AU - Rogowski-Lehmann, Natalie
AU - Reincke, Martin
AU - Beuschlein, Felix
AU - Fassnacht, Martin
AU - Lalli, Enzo
N1 - Publisher Copyright:
Copyright © 2017 Endocrine Society.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Context: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with overall poor prognosis. The Ki67 labeling index (LI) has amajor prognostic role in localized ACC after complete resection, but its estimates may suffer from considerable intra- and interobserver variability. VAV2 overexpression induced by increased Steroidogenic Factor-1 dosage is an essential factor driving ACC tumor cell invasion. Objective: To assess the prognostic role of VAV2 expression in ACC by investigation of a large cohort of patients. Design, Setting, and Participants: A total of 171 ACC cases (157 primary tumors, six local recurrences, eightmetastases) from seven European Network for the Study of Adrenal Tumors centers were studied. Outcome Measurements: H-scores were generated to quantify VAV2 expression. VAV2 expression was divided into two categories: low (H-score,2) and high (H-score,$2). The Ki67 LI retrieved from patients' pathology records was also categorized into low (,20%) and high ($20%). Clinical and immunohistochemical markers were correlated with progression-free survival (PFS) and overall survival (OS). Results: VAV2 expression and Ki67 LI were significantly correlated with each other and with PFS and OS. Heterogeneity of VAV2 expression inside the same tumor was very low. Combined assessment of VAV2 expression and Ki67 LI improved patient stratification to low-risk and high-risk groups. Conclusion: Combined assessment of Ki67 LI and VAV2 expression improves prognostic prediction in ACC.
AB - Context: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with overall poor prognosis. The Ki67 labeling index (LI) has amajor prognostic role in localized ACC after complete resection, but its estimates may suffer from considerable intra- and interobserver variability. VAV2 overexpression induced by increased Steroidogenic Factor-1 dosage is an essential factor driving ACC tumor cell invasion. Objective: To assess the prognostic role of VAV2 expression in ACC by investigation of a large cohort of patients. Design, Setting, and Participants: A total of 171 ACC cases (157 primary tumors, six local recurrences, eightmetastases) from seven European Network for the Study of Adrenal Tumors centers were studied. Outcome Measurements: H-scores were generated to quantify VAV2 expression. VAV2 expression was divided into two categories: low (H-score,2) and high (H-score,$2). The Ki67 LI retrieved from patients' pathology records was also categorized into low (,20%) and high ($20%). Clinical and immunohistochemical markers were correlated with progression-free survival (PFS) and overall survival (OS). Results: VAV2 expression and Ki67 LI were significantly correlated with each other and with PFS and OS. Heterogeneity of VAV2 expression inside the same tumor was very low. Combined assessment of VAV2 expression and Ki67 LI improved patient stratification to low-risk and high-risk groups. Conclusion: Combined assessment of Ki67 LI and VAV2 expression improves prognostic prediction in ACC.
UR - http://www.scopus.com/inward/record.url?scp=85031104940&partnerID=8YFLogxK
U2 - 10.1210/jc.2017-00984
DO - 10.1210/jc.2017-00984
M3 - Article
C2 - 28911143
AN - SCOPUS:85031104940
SN - 0021-972X
VL - 102
SP - 3491
EP - 3498
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 9
ER -